On the stock market since 2018, it operates in the world of health and science. It has 20 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $2.7M against $0 in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0080. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, PNDHF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PNDHF is a high-risk stock — not yet profitable, and its future rides on its product catching on.